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Background: Steroid Responsive Meningitis-Arteritis (SRMA) is a common cause of inflammation of the canine
central nervous system (CNS). To investigate if transforming growth factor beta 1 (TGF-β1), interleukin-6 (IL-6) and
vascular endothelial growth factor (VEGF) are involved in the production of excessive immunoglobulin A (IgA), the
induction of acute phase proteins and in the development of a systemic necrotizing vasculitis, characteristic of
SRMA, these three signalling proteins were evaluated.
Results: Cerebrospinal fluid (CSF) and serum samples of dogs during the acute phase of SRMA (SRMA) were tested
for IL-6, VEGF and TGF- β1. Results were compared to those of dogs affected with SRMA during treatment (SRMA
Th) and during relapse (SRMA R), to dogs with other meningoencephalomyelitides (ME), with miscellaneous
non-inflammatory diseases of the CNS (CNS-Mix), with idiopathic epilepsy (IE), with systemic inflammatory diseases
(Syst. Infl.) and with healthy dogs (Healthy). Concentrations of IL-6 and VEGF in CSF were significantly elevated in
the SRMA group compared to the other disease categories (p < 0.05). The CSF concentrations of TGF-β1 were
increased in SRMA group, but statistically significant differences were found only in comparison with Healthy and
CNS-Mix groups. No differences were detected in the serum concentrations of TGF-β1 between the different
groups. In untreated SRMA patients, a positive correlation (rSpear = 0.3549; P = 0.0337) between concentrations of
TGF-β1 and IgA concentration was found in CSF, while concentrations of IL-6 and VEGF in CSF positively correlated
with the degree of pleocytosis (rSpear = 0.8323; P < 0.0001 and rSpear = 0.5711; P = 0.0166, respectively).
Conclusions: Our results suggest that these three signalling proteins are biomarkers of disease activity in SRMA.
VEGF might play an important role in the development of a systemic arteritis. TGF-β1 is considered to be involved
in the excessive IgA production, while IL-6 in the pleocytosis. The combined intrathecal increase of TGF-β1 and IL-6
detected in SRMA could possibly force CD4 progenitors to differentiate towards the newly described Th17
lymphocyte subset and enhance the autoimmune response.
Keywords: Steroid responsive meningitis-arteritis (SRMA), Interleukin-6 (IL-6), Transforming growth factor beta 1
(TGF-β1), Vascular endothelial growth factor (VEGF), Cerebrospinal fluid (CSF), Dog, Central nervous system (CNS)
Background severe neck pain in addition to signs of systemic illness,
Steroid Responsive Meningitis-Arteritis (SRMA) is a rela-
tively common inflammatory disease of the canine central
nervous system (CNS) [1], being the primary cause of
meningitis [2,3] and one of the most common causes of
fever in referred dogs [4]. Typically affected dogs manifest* Correspondence: arianna.maiolini@tiho-hannover.de
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reproduction in any medium, provided the orsuch as fever and lethargy. The meningeal and systemic
inflammation is usually reflected by laboratory findings,
such as pleocytosis and leukocytosis [5] and the elevation
of acute phase proteins [6-8]. A concurrent increased
intrathecal and systemic production of immunoglobulin A
(IgA) has been found in dogs affected with SRMA [9], and
its determination supports the diagnosis [10]. Recent stud-
ies underlined the importance of a Th2-mediated immune
response in SRMA patients [11,12], but the exact etio-
pathogenesis of the disease is still unclear.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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growth factors, hormones and neurotransmitters, that
interact with receptors. Vascular Endothelial Growth
Factor (VEGF) is a potent, multifunctional factor, which
regulates angiogenesis and blood vessel permeability
[13,14]. In the last two decades the role of VEGF has
been widely investigated in systemic vasculitides [15-17]
and malignant tumours [18,19]. In veterinary medicine
VEGF has been studied in some inflammatory diseases
[20] and tumours [21,22], but its role in systemic vascu-
litis is still unknown. Interleukin 6 (IL-6) is a proinflam-
matory cytokine, which activates lymphocytes, increases
antibody production, induces fever and acute-phase pro-
tein production [23], while Transforming Growth Factor
Beta 1 (TGF-β1) induces a class switching of B lympho-
cytes towards IgA production [24].
To test the hypothesis that the signalling proteins
VEGF, IL-6 and TGF-β1 are involved in the pathogenesis
of SRMA, these proteins were determined in cerebro-
spinal fluid (CSF) and serum. We hypothesize that
enhanced VEGF production is responsible for the
increased vascular permeability (vasculitis) observed in
SRMA dogs, while IL-6 and TGF-β1 are responsible for
the excessive IgA production and the systemic inflam-
matory response, especially for acute phase protein pro-
duction and development of T-helper cell subtypes.Methods
Serum and cerebrospinal fluid (CSF) samples
Serum and cerebrospinal fluid (CSF) samples were col-
lected from client-owned dogs, presented to the Neur-
ology Service of the Department of Small AnimalTable 1 Distribution of disease categories
Groups F
SRMA untreated (SRMA) D
T
SRMA relapse (SRMA R) D
d
SRMA therapy (SRMA Th) D
g
s






Miscellaneous non-inflammatory CNS diseases (CNS-Mix). D
d
c
Systemic inflammatory diseases (Syst. Inflam.) D
n
Healthy H
CSF: cerebrospinal fluid; CNS: central nervous system; MRI: magnetic resonance imaMedicine and Surgery, University of Veterinary Medicine,
Hannover, Germany, according to the Universities rules.
All dogs underwent a standard neurological examin-
ation performed either by a veterinary neurology resident
or a board-certified veterinary neurologist. Depending on
the diagnosis, animals were assigned to one of the follow-
ing groups (see Table 1): ‘SRMA untreated’ (SRMA),
‘SRMA relapse’ (SRMA R), ‘SRMA therapy’ (SRMA Th),
‘idiopathic epilepsy’ (IE), ‘Meningoencephalomyelitides’
(ME), and ‘miscellaneous non-inflammatory CNS diseases’
(CNS-Mix).
Diagnoses were based on the results of general and
neurological examinations, complete blood cell count
(CBC), blood chemistry, CSF analysis and further spe-
cific diagnostic procedures if considered useful to
achieve a definitive or ‘highly likely’ diagnosis (e.g. radio-
graphic and ultrasound examination, electrodiagnostics,
computed tomography, magnetic resonance imaging,
surgery, histopathology).
Dogs not suffering from neurological conditions, but
otherwise affected with systemic inflammatory diseases
were also included in the study (‘Syst. Inflam.’).
Healthy dogs with a normal general and neurological
examination and laboratory values in the reference range
served as negative control group (‘Healthy’).
CSF and serum samples were stored at −20°C until
batch analyzed.
The study was conducted following the ethical guide-
lines of the University for Veterinary Medicine
Hannover. The experimental protocols and procedures
in healthy dogs were performed in accordance with the
European Communities Council Directive of 24 Novem-
ber 1986 (86/609/EEC) and were approved by theindings and number of dogs
ogs with fever, cervical pain, neutrophilic leukocytosis and pleocytosis.
hese dogs were not pre-treated with glucocorticosteroid (n = 36)
ogs with a previous diagnosis of SRMA in which clinical signs recurred
espite glucocorticosteroid treatment (n = 9)
ogs with previous diagnosis of SRMA under long-term
lucocorticosteroid treatment. These dogs did not show any clinical
igns at the time of sampling (n = 20)
ogs with clinical, CSF, MRI findings consistent with idiopathic epilepsy
= 22)
ogs with clinical, CSF, MRI and/or pathological findings consistent with
eningoencephalomyelitides: granulomatous meningoencephalomyelitis
= 14), necrotising encephalitides (n = 1), meningoencephalomyelitis of
nknown origin (n = 8), infectious encephalitides (n = 24)
ogs with miscellaneous not primarily inflammatory neurological
iseases: intervertebral disc disease (n = 9), neoplasia of the CNS (n = 24),
erebrovascular disease (n = 4), degenerative myelopathy (n = 1)
ogs affected with systemic inflammatory diseases, but not suffering from
eurological conditions (n = 16)
ealthy dogs (n = 20)
ging; SRMA: steroid-responsive meningitis-arteritis.
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33.42502/05-12.05).
Quantification of IL-6
Serum and CSF IL-6 concentrations were measured with a
commercially available canine-specific Enzyme Linked Im-
munosorbent Assay (ELISA) following manufacturer’s
instructions (Quantikine Canine IL-6 Immunoassay; R&D
Systems, Minneapolis, MN, USA). The mean minimum
detectable value given by the manufacturer was 6.1 pg/mL.
Values lower than 6.1 pg/mL, were considered negative
for IL-6. If the value ranged between 6.1 pg/mL and the
highest dilution of the standard curves (31.25 pg/mL) a
fixed value of 3 pg/mL was assigned for statistical analysis.
If the value exceeded the highest value of the standard
curve (2000 pg/mL), the sample was diluted and measured
again.
All samples were analyzed in duplicates and mean
values were calculated.
The IL-6 bioactivity in serum and CSF was verified
testing its ability to stimulate proliferation of B9 cell line,
a mouse B cell murine hybridoma cell line that requires
IL-6 for survival and proliferation (DSMZ No ACC 211,
German Collection of Microorganisms and Cell Cul-
tures, DSMZ, Braunschweig, Germany) [25-28].
Cells were cultured at 37°C and 5% CO2 in Rosewell
Park Memorial Institute (RPMI) 1640 medium with L-
glutamine (GibcoW RPMI Media 1640) containing 10%
heat-inactivated fetal bovine serum, 50 pg/mL recombin-
ant canine IL-6 (rcIL-6) (Recombinant Canine IL-6;
R&D Systems, Minneapolis, MN, USA) and 50 μM 2-
mercaptoethanol.
Cells for the assay were washed twice in the above
described medium without IL-6. For each assay, a stand-
ard curve was prepared using rcIL-6 with serial threefold
dilutions starting at 200 pg/mL.
Samples were tested in duplicates at dilutions ranging
from 1:2 to 1: 240.
For the IL-6 bioactivity assay B9 cells (5000 cells/well)
were incubated for 48 hours with rcIL-6 standard dilutions
or diluted canine CSF and serum samples in opaque 96-
well microtiter plates (F96 MicroWell™ Plates, Nunc™,
Denmark). Cell proliferation and viability was quantified
using the CellTiter-GloW Luminescent Cell Viability Assay
(Promega, Madison, WI), according to manufacturer’s
recommendations. Luminescence in each well was mea-
sured 30 min after reagent addition using a scanning multi-
well spectrophotometer equipped with the analysis software
Gen 5 (Synergy2 HT multi-mode microplate reader, BioTek
Instruments Inc., Bad Friedrichshall Germany).
Quantification of VEGF
Serum and CSF VEGF concentrations were measured with
commercially available canine-specific ELISA followingmanufacturer’s instructions (Quantikine Canine VEGF
Immunoassay, R&D Systems, Minneapolis, MN, USA).
The minimum detectable values given by the manufac-
turer were < 9.8 pg/mL for CSF and < 19.5 pg/mL for
serum. Similarly as described for the IL-6 ELISA, a content
of 0 pg/mL was assigned if the amount of VEGF detected
was less than the minimum detectable concentration.
If the amount ranged between 9.8 pg/mL for CSF or
19.5 pg/mL for serum and the highest dilution of the
standard curves (19.5 pg/mL and 39.1 pg/mL, respect-
ively) a fixed value of 2 pg/mL and 3.9 pg/mL instead of
zero was assigned for statistical analysis.
All samples were analyzed in duplicates and mean
values were calculated.Quantification of TGF-β1
Serum and CSF TGF-β1 concentrations were measured
with a commercially available ELISA following manufac-
turer’s instructions (Human TGF-beta 1 DuoSet, R&D
Systems, Minneapolis, MN, USA ). This assay is designed
to detect the biologically active natural and recombinant
human TGF-β1. Canine TGF-β1 shares 94% nucleotide
sequence identity to human TGF-β1 [29]. Therefore, we
suspected a relative high cross-reactivity that allows the
measurement of canine TGF-β1 by using this human
ELISA Development Kit. The final dilution was 1:15 for
the CSF samples and 1:30 and 1:60 for the serum sam-
ples. All dilutions were tested in duplicates on 96-well
microplates (Nunc-Immuno™-Plate, Nunc™, Denmark).
The absorbance was recorded at a wavelength of 450 nm
using a plate reader (Dynatech, Denkendorf, Germany).
Antibodies were tested by immunohistochemistry
(IHC) detecting canine TGF-β1 on canine tissue. Differ-
ent canine tissues (activated lymph nodes, brain tumour,
brain and spinal cord from SRMA affected dogs) were
stained with the capture antibody of the previously men-
tioned ELISA-Kit. All tissues were routinely formalin-
fixed and paraffin-embedded and the sections were
mounted on positively charged slides (SuperFrost PlusW,
Menzel-Gläser, Wiesbaden, Germany). Tissue sections
were deparaffinised and the endogenous peroxidase was
blocked with 0.5% H2O2 in 70% ethanol over 30 minutes.
After washing the slides with PBS three times for five
minutes, citrate buffer (10 minutes, autoclave, 121°C)
was used for antigen retrieval. The capture antibody of
the ELISA-Kit, a monoclonal mouse-anti-human TGF-
β1-antibody was diluted 1:40 in PBS (pH 7.5) with 1%
bovine serum albumin (BSA) and incubated overnight by
4°C. As secondary antibody we used a biotinylated goat-
anti-mouse-antibody (Vector Laboratories, Burlingame,
USA) (diluted 1:200 in PBS, incubation for 45 minutes,
room temperature). Staining was completed using an ABC
Kit (Vector Laboratories, Burlingame, USA).
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Serum and CSF IgA concentration were measured in 31
dogs with ‘untreated SRMA’ using an ELISA, as previ-
ously described [9].
Data analysis
Data were analyzed for normal distribution using the
Kolmogorov-Smirnov test, and non-parametric tests
were used to analyze data not conforming to a Gaussian
distribution.
In addition to descriptive methods, the Kruskal-Wallis
test was used to evaluate the analysis of variance. Mul-
tiple comparisons between the SRMA groups and
groups of other diseases were performed using the Wil-
coxon rank-sum test.
The Spearman’s rank correlation coefficients (rSpear)
were calculated in the “SRMA untreated” group to de-
tect correlations between signalling proteins and differ-
ent parameters, such as IgA concentrations, complete
blood cell count and CSF cell count.
Data were analyzed by using the statistical software
package (GraphPad PrismW, version 5; GraphPad Soft-
ware, La Jolla, CA, USA) and values of P < 0.05 were
considered significant.
Results
CSF and serum samples of 172 dogs were collected and
analysed. In additional 36 dogs only serum was collected.
The small amount of some of the samples did not allow
performing the quantification of all three signalling pro-
teins in each sample. The distribution of the samples for
each ELISA is shown in Table 2.
Quantification of IL-6
IL-6 concentrations in CSF and serum and results of the
statistical analysis are illustrated in Figure 1A and 1BTable 2 Number of CSF and serum samples analysed for
each signalling protein in each group
Groups IL-6 VEGF TGF-β1
n of samples CSF Serum CSF Serum CSF Serum
SRMA 26 28 21 28 36 35
SRMA R 9 8 9 8 0 0
SRMA Th 41 44 41 45 0 0
ME 13 13 11 17 39 35
CNS-Mix 21 22 18 20 29 26
Syst. Inflam. 7 12 3 16 0 0
IE 22 16 14 14 0 0
Healthy 8 8 8 8 20 15
IL-6: interleukin-6; VEGF: vascular endothelial grow factor; TGF-β1:
Transforming growth factor beta; CSF: cerebrospinal fluid; CNS: central nervous
system; SRMA: steroid-responsive meningitis-arteritis; Syst Inflam: systemic
inflammatory diseases; ME: other inflammatory CNS diseases; CNS-Mix:
miscellaneous non-inflammatory CNS diseases; IE: idiopathic epilepsy.and Table 3. The highest concentrations of IL-6 were
detected in CSF of dogs with SRMA (median 1582 pg/mL;
range 163.1-3473 pg/mL). This group differed significantly
from the other disease categories, with the exception of
dogs with relapsed SRMA (median 637.7 pg/mL; range
17.19-1507 pg/mL).
Similarly, high concentrations of IL-6 were detected in
serum in the ‘SRMA’ group (median 3 pg/mL; range 3–
124 pg/mL), ‘SRMA R’ group (median 17.13 pg/mL;
range 3–36.24 pg/mL) and ‘Syst. Inflam.’ group (median
17.13 pg/mL; range 0–77.1 pg/mL). In the remaining
groups the IL-6 concentration was significantly lower
than in the ‘SRMA’ group.
Approximately 30% of the samples used for the ELISA
were also tested with the bioassay.
The B9 cells could proliferate only when incubated
with samples with high IL-6 values measured by the
ELISA.Quantification of VEGF
VEGF concentrations in CSF and serum and results of the
statistical analysis are illustrated in Figure 1C and 1D and
Table 3.
The highest concentrations of VEGF were detected in
CSF (median 36.31 pg/mL; range 1–175.2 pg/mL) and
serum (median 43.92 pg/mL; range 3.9-94.5 pg/mL) of
dogs with SRMA. Similarly, high concentrations of
VEGF were found in CSF (median 20.80 pg/mL; range
0–69.96 pg/mL) and serum (median 33.71 pg/mL; range
0.98-42.9 pg/mL) of dogs with relapsed SRMA and in
serum (median 3.9 pg/mL; range 3.9-57.8 pg/mL) of
dogs with a systemic inflammatory disease. In the
remaining groups the VEGF concentrations were signifi-
cantly lower than the ones of the ‘SRMA’ group.Quantification of TGF-β1
TGF-β1 concentrations in CSF and serum and results of
the statistical analysis are illustrated in Figure 1E and F
and Table 3.
Compared with the ‘Healthy’ group, TGF-β1 concen-
trations in CSF were significantly higher in the ‘SRMA’
(median 90 pg/mL; range 0–429 pg/mL) and the ‘ME’
(median 58 pg/mL; range 0–214 pg/mL) groups. In
serum the ‘SRMA’ group showed the lowest concentra-
tions of TGF-β1 (median 13.57 ng/mL, range 9.93-
19.27 ng/mL). These concentrations were significantly
lower than those found in the remaining groups.
The capture antibody of the commercial human
ELISA-Kit succeeded in staining canine TGF-β1 in the
canine tissues used as positive controls, such as lymph
nodes with suppurative lymphadenitis and brain and
spinal cord with SRMA (Figure 2). In the negative con-
trol sections no TGF-β1 was detected.
Figure 1 Quantification of signalling proteins. Quantification of signalling proteins: IL-6 in CSF (A) and serum (B), VEGF in CSF (C) and serum
(D), TGF-β1 in CSF (E) and serum (F). Boxes contain values from 1st to 3rd quartile, lines inside boxes indicate median values, endpoints of vertical
lines display 5th–95th percentile and • represent the outliers. Asterisks indicate statistically significant differences from the disease category ‘SRMA
untreated’ (* P < 0.05; ** P < 0.01; *** P < 0.005). IL-6: interleukin-6; VEGF: vascular endothelial grow factor; TGF-β1: Transforming growth factor beta
1. CSF cerebrospinal fluid; CNS: central nervous system; SRMA: steroid-responsive meningitis-arteritis; ME: other inflammatory CNS diseases; CNS-
Mix: miscellaneous non-inflammatory CNS diseases; Syst Inflam: systemic inflammatory diseases; IE: idiopathic epilepsy.
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The data of the parameters correlating with the signal-
ling proteins within the untreated SRMA group are
shown in Table 4. A summary of the statistically relevant
correlations found in the ‘SRMA’ group is shown inTable 5. A weak positive correlation between signalling
protein and IgA concentration was found between CSF
TGF-β1 and CSF IgA (rSpear = 0.3549; P = 0.0337).
CSF concentrations of IL-6 and VEGF had a strong
positive correlation with the degree of pleocytosis
Table 3 Concentration of signalling proteins in different disease categories
SRMA SRMA R SRMA Th Syst Inflam ME CNS-Mix IE Healthy
IL-6 CSF 1582 637.7 0 0 3 0 0 3
(pg/mL) (163.1-3473) (17.19-1507) (0–1.5) (0–31.25) (0–175.6) (0–3) (0–3) (0.75-3)
Serum 3 17.13 0 17.13 0 0 1.5 3
(pg/mL) (3–124) (3–36.24) (0–0) (0–77.1) (0–3) (0–3) (0–3) (0–3)
VEGF CSF 36.31 20.80 0 0 0 0 0 0
(pg/mL) (1–175.2) (0–69.96) (0–0) (0–0) (0–65.71) (0–0) (0–0) (0–0)
Serum 43.92 33.71 3.9 3.9 0 0 0 3.9
(pg/mL) (3.9-94.5) (0.98-42.9) (0–3.9) (3.9-57.8) (0–3.9) (0–3.9) (0–0) (1.95-3.9)
TGF-β1 CSF 90 n.a. n.a. n.a. 58 0 n.a. 0
(pg/mL) (0–429) (0–214) (0–95) (0–0)
Serum 13.57 n.a. n.a. n.a. 22.84 19.31 n.a. 23.84
(ng/mL) (9.93-19.27) (11.86-27.96) (14.77-23.25) (18.19-29.16)
IL-6: interleukin-6; VEGF: vascular endothelial grow factor; TGF-β1: Transforming growth factor beta; CSF: cerebrospinal fluid; CNS: central nervous system;
SRMA: steroid-responsive meningitis-arteritis; Syst Inflam: systemic inflammatory diseases; ME: other inflammatory CNS diseases; CNS-Mix: miscellaneous
non-inflammatory CNS diseases; IE: idiopathic epilepsy; n.a.: not available. Data are given as median and range (25th–75th percentile).
Figure 2 Spinal cord and meninges of a dog with SRMA. Arrow
indicates TGF-β1 positive lymphocyte; immunohistochemistry, anti-
TGF-β1-ABC, x400. SRMA: steroid-responsive meningitis-arteritis. TGF-
β1: Transforming growth factor beta 1.
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respectively). A strong positive correlation was also found
between concentration of IL-6 and VEGF, both in CSF
(rSpear = 0.8246; P < 0,0001) and serum (rSpear = 0.5045;
P = 0.0086). A similar correlation was not found in serum
of ‘Syst Inflam.’ group (rSpear = 0.1340; P = 0.339).Discussion
The aim of the present study was to investigate the role
of IL-6, VEGF and TGF-β1 in the pathogenesis of
SRMA.
VEGF concentrations were measured, since this par-
ameter has been widely studied in human patients
affected with Kawasaki Disease (KD), an acute febrile
systemic vasculitis of children. SRMA has been proposed
as an animal model for KD [30,31]. In KD patients,
concentrations of VEGF were found significantly ele-
vated [16,17,32]. The histopathology of meningeal arter-
ies of dogs euthanised during the acute stage of SRMA
typically revealed endothelial and subendothelial oedema,
hyaline degeneration and a mild to moderate periarteritis
[33]. Therefore, we hypothesized that elevated VEGF
might cause these early vascular changes. Indeed, our
results showed that VEGF was increased both systemicallyTable 4 Parameters investigated for the group ‘SRMA’
Concentration of IgA Number of leukocytes
CSF 2 CSF 1532
(μg/mL) (0.86-3.1) cells/3μL) (548–3720)
Serum 167.4 PB 25635
(μg/mL) (98.90-404.5) (cells/μL) (17250–31533)
CSF: cerebrospinal fluid; SRMA: steroid-responsive meningitis-arteritis; PB:
peripheral blood. Data are given as median and range (25th–75th percentile).
Table 5 Significant correlations for the group ‘SRMA’
Evaluated parameters Spearman’s rank correlation coefficient
Concentration of IL-6 in CSF Concentration of VEGF in CSF 0.8246***
Concentration of IL-6 in serum Concentration of VEGF in serum 0.5045**
Concentration of IL-6 in CSF Number of leukocytes in CSF 0.8323***
Concentration of VEGF in CSF Number of leukocytes in CSF 0.5711*
Concentration of TGF-β1 in CSF Concentration of IgA in CSF 0.3549*
SRMA: steroid-responsive meningitis-arteritis; IL-6: interleukin-6; VEGF: vascular endothelial grow factor; TGF-β1: Transforming growth factor beta; IgA:
immunoglobulin A; CSF: cerebrospinal fluid. Data are given as median and range (25th–75th percentile).
*P < 0.05; ** P < 0.01; *** P < 0.005.
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phases of the disease (‘SRMA’ and ‘SRMA R’). At these
time points the mentioned vascular changes can be
observed [33].
In other different inflammatory processes within the
CNS (“ME” group), VEGF was found to be increased
only in single cases, but overall the CSF VEGF concen-
trations in this group was significantly lower than in the
SRMA group. We might conclude that VEGF does not
play an important role in other meningoencephalomyeli-
tides. However, due to the heterogeneity of the diseases
included in the ME group (e.g. granulomatous menin-
goencephalomyelitis, necrotising encephalitides and
meningoencephalomyelitis of unknown origin) we can
not exclude from this study a role for VEGF in some of
these diseases.
The values of VEGF in cases with systemic inflamma-
tion were lower than in dogs with SRMA (median
3.9 pg/mL and 43.92 pg/mL, respectively). However, the
difference was not statistically significant. This is in ac-
cordance with a recent study in which VEGF values were
elevated in 64% of dogs with systemic inflammatory re-
sponse syndrome. However, a correlation with clinical
signs or increased permeability could not be proved [20].
VEGF is involved in the proposed pathogenesis of vas-
culitis in KD. After the permeability of the vessels is
increased under to the influence of VEGF, platelets
might adhere to the vascular wall and inflammatory cells
cross the loose endothelium, accumulating in the intima
and becoming a source of proinflammatory cytokines.
As final consequence there is a thickening of the intima
as found in both diseases, KD and SRMA. If coronary
artery lesions occur, this might even lead to life-
threatening complications [31]. In KD patients VEGF
was correlated with the development of coronary artery
lesions [32].
Interestingly in our study VEGF was not only found
increased in the acute stage of SRMA, but also during
relapses of SRMA (median in CSF 20.80 pg/mL; median
in serum 33.71 pg/mL). Therefore, VEGF in SRMA may
enhance vascular wall destruction in the acute phase of
the disease before immune complexes appear [33]. How-
ever, further in vitro studies evaluating directly the effectof VEGF on canine vasculature (e.g. using endothelial
cells culture or cultured vessels) are needed to confirm
the role of this protein in the pathogenesis of canine
arteritis.
Since VEGF concentrations were increased during
relapses, consequently, VEGF may be also involved in
the development of the arterial lesions found during the
chronic phase, such as increased wall thickness, stenosis
and fibrosis [33]. On the other hand, VEGF might indi-
cate simply vascular damage. A limitation of this study is
the lack of comparison to other pure vasculitides. Ex-
perimental in vivo studies are probably necessary to elu-
cidate the long-term effect of VEGF on canine vessels.
Experimental studies on SRMA dogs are feasible, due to
the natural occurrence and the favourable prognosis of
the disease.
The recruitment and activation of different lympho-
cytes subsets after alteration of the CNS tissue by an en-
vironmental factor are caused by multiple mechanisms
[34]. These include chemotactic agents [35], probably
additional mechanisms such as changes of the blood–
brain barrier [36,37], and altered expression of selectins
and integrins [38,39]. To add more information to these
previous studies and to investigate the hypothesis that
IL-6 and TGF-β1 are correlated to and eventually
involved in the pathogenesis of fever, pleocytosis and
increased IgA production in SRMA, these proteins were
determined in CSF and serum samples. Previous studies
on cytokine expression in SRMA patients, showed an
up-regulation of IL-4 and IL-8, while IL-2 and IFN-γ
were found in low concentrations [12,35]. Hogenesch
et al. [40] investigated IL-6 in serum of dogs with juven-
ile polyarteritis syndrome and detected increased IL-6
serum values. In preliminary studies, measurement of
IL-6 in CSF was considered to be a valuable biomarker
for the diagnosis of SRMA [41]. Qualitative studies con-
taining information about the bioactivity of IL-6 in CSF
were missing.
In the current study IL-6 values were increased intra-
thecally and systemically in SRMA patients, the highest
concentrations were found in CSF samples (median
1582 pg/mL in ‘SRMA’ and median 637.7 pg/mL in the
‘SRMA R’ groups). In case of other inflammatory
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CSF IL-6 were significantly lower (median 3 pg/mL),
leading to the conclusion that IL-6 is an important bio-
marker for disease activity in SRMA. The exact role of
IL-6 in the pathogenesis of the disease could be investi-
gated in experimental studies. Further, IL-6 in SRMA
strongly correlated with the degree of pleocytosis. This
fact might also suggests, that IL-6 values might be the
result of the severe pleocytosis because of its production
by macrophages [23]. Lowrie et al. [41] also detected ele-
vated IL-6 CSF values in samples of dogs with a putative
relapse and a normal CSF cell count, making the latter
hypothesis less likely, nevertheless further studies should
be addressed to clarify causes and consequences.
IL-6 has long-range effects, indeed it is one of the
most important endogenous pyrogens, induces hepato-
cytes to synthesize acute-phase proteins, stimulates neu-
trophil mobilization from bone marrow and stimulates
terminal differentiation of B cells to secret immunoglo-
bulins [23,42,43]. Therefore it is very likely that an over-
production of IL-6 is a major mediator of the most
peculiar findings, such as fever, increased acute-phase
proteins, CSF neutrophilic pleocytosis and peripheral
leukocytosis as well as increased IgA production during
the acute phase of SRMA. The extreme high values of
IL-6 in CSF also during relapses suggest that IL-6 exerts
its major functions intrathecally and throughout the
waxing and waning course of the disease. As previously
mentioned, the cell population in CSF of dogs during
the acute phase of SRMA is predominantly composed of
neutrophils, during the chronic form macrophages tend
to prevail. Upregulation of CD11a on neutrophils [39],
increased IL-8 levels in CSF [35] and the destruction of
the blood–brain barrier [44] have all been shown to be
involved in neutrophil migration into CSF. Factors
involved in the accumulation of monocytes in CSF of
SRMA patients during the protracted form have not
been investigated. Interestingly, IL-6 has been recently
proposed to be a regulator of the transition from a
neutrophil-dominated to a macrophage-dominated process
[45]. We therefore propose a leading role for IL-6 in both
the acute and protracted forms of the disease.
As expected, serum IL-6 concentrations were similar
to the group of systemic inflammatory diseases support-
ing other studies, where IL-6 has been used not only as
a general marker of inflammation [26], but in particular
as a prognostic factor in canine systemic inflammatory
response syndrome and sepsis [27]. Also in KD IL-6 is
increased in serum, but contrary to VEGF, the increase
was not correlated with the development of coronary ar-
tery aneurysms and dilatation [46,47].
In SRMA dogs both VEGF and IL-6 were much higher
in CSF compared to serum values. This might reflect a
more severe inflammatory process affecting meningesand meningeal vessels compared to peripheral vessels, or
a main intrathecal production of these signalling pro-
teins, followed by a secondary leakage into the systemic
circulation. Further studies including protein associated
gene expression and immunohistochemistry of menin-
geal and peripheral vessels might be necessary to eluci-
date the site of production.
TGF-β1 in SRMA patients was decreased in serum
(median 13.57 ng/mL) and elevated in CSF (median
90 pg/mL). The increased concentration in CSF was not
specific for SRMA, indeed similar values have been
found in other meningoencephalomyelitides (median
58 pg/mL), while the reduced concentration in serum
statistically differed from the other groups.
The serum concentrations of TGF-β1 were found to be
decreased also in patients with KD [48], but to the
authors knowledge data concerning concentrations of
TGF-β1 in CSF of patients with KD are lacking. The hy-
pothesis that TGF-β1 might be the most important
pathogenetic factor for the excessive IgA production in
SRMA could be partially rejected in the current study.
Our results support the suggestion that TGF-β1 has a
minor role in systemic production of IgA, whereas it is
highly likely that it might still play a certain role in the
intrathecal production of IgA. Indeed, TGF-β1 was posi-
tively correlated with IgA concentrations in CSF (rSpear =
0.3549; P = 0.0337). However, CSF IgA concentrations re-
main high during teatment [5,8,10] and concentration of
TGF-β1 decline. Therefore, this rather unspecific eleva-
tion of TGF-β1 values in CSF samples supports a more
immunoregulatory function of this cytokine in inflamma-
tory CNS diseases [49,50]. Further experimental in vivo
and in vitro studies are needed to confirm this hypothesis.
Our findings indicate that the CSF cytokine profile of
SRMA dogs during the acute phase is characterized by
increased values of IL-6 and TGF-β1. Recent progress in
immunology led to the discovery of Th17 cells, a new
subset of T helper cells [51,52]. According to one study,
the combined influence of both IL-6 and TGF-ß1 is ne-
cessary for the Th17 lineage to develop, while TGF-β1
alone shifts the development of naïve T-cells towards T
regulatory cells, a T-cell subset that restrains inflamma-
tion and maintains tolerance [53].
The detected combined high intrathecal production of
TGF-β1 and IL-6 in SRMA could possibly lead to an in-
crease of Th17 lymphocyte subset and subsequently
enhance the development of an autoimmune response.
IL-17, the main product of this lymphocyte subset, plays
an active role in inflammatory response and in auto-
immune diseases [54] and experimental studies displayed
a neutrophil-mobilizing mechanism of IL-17A [55]. The
massive invasion of neutrophils into the subarachnoidal
space in SRMA dogs might be the results of a Th17 im-
mune response. Further studies to prove direct evidence
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be conducted.
To date, SRMA has been believed to be a Th2-
mediated immune disorder [12], our results suggest in-
directly that in SRMA a Th17 skewed immune response
might play a major role, particularly in the development
of the meningitis.
Conclusions
Analysis of the pattern of signalling proteins production
in SRMA showed many similarities with results in KD
supporting the usefulness of this animal model. In our
study increased concentrations of VEGF and IL-6 in
serum and CSF of dogs affected with SRMA were found.
TGF-β1 was increased in CSF and decreased in serum.
This study produces evidence that these three signalling
proteins are biomarkers of disease activity in SRMA.
VEGF might be involved in the pathogenesis of vascu-
litis, especially in a pronounced permeability and vessel
wall damage. TGF-β1 is considered to be involved in the
excessive IgA production. However, the presented data
indicate that additional proteins may influence IgA pro-
duction. Pleocytosis in SRMA dogs is supported by ex-
tremely high intrathecal IL-6 production; a similar
pathomechanism might be responsible for the continuous
ongoing of the disease and the invasion of neutrophils. The
hypothesis that SRMA might be a Th17-mediated disorder
should be further investigated.
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